Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer
Chemotherapy has become the global standard treatment for patients with metastatic or unresectable gastric cancer (GC), although outcomes remain unfavorable. Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed, and monoclonal antib...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/796380 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567276422823936 |
|---|---|
| author | Mikito Inokuchi Yoshitaka Fujimori Sho Otsuki Yuya Sato Masatoshi Nakagawa Kazuyuki Kojima |
| author_facet | Mikito Inokuchi Yoshitaka Fujimori Sho Otsuki Yuya Sato Masatoshi Nakagawa Kazuyuki Kojima |
| author_sort | Mikito Inokuchi |
| collection | DOAJ |
| description | Chemotherapy has become the global standard treatment for patients with metastatic or unresectable gastric cancer (GC), although outcomes remain unfavorable. Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed, and monoclonal antibodies targeting human epidermal growth factor receptor 2 (HER2) have become standard therapy for HER2-positive GC. An inhibitor of vascular endothelial growth factor receptor 2 or MET has also produced promising results in patients with GC. Fibroblast growth factor receptors (FGFR) play key roles in tumor growth via activated signaling pathways in GC. Genomic amplification of FGFR2 leads to the aberrant activation found in GC tumors and is related to survival in patients with GC. This review discusses the clinical relevance of FGFR in GC and examines FGFR as a potential therapeutic target in patients with GC. Preclinical studies in animal models suggest that multitargeted tyrosine kinase inhibitors (TKIs), including FGFR inhibitor, suppress tumor cell proliferation and delay tumor progression. Several TKIs are now being evaluated in clinical trials as treatment for metastatic or unresectable GC harboring FGFR2 amplification. |
| format | Article |
| id | doaj-art-f909ad67768949e492a74560fa04bc1e |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-f909ad67768949e492a74560fa04bc1e2025-02-03T01:02:05ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/796380796380Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric CancerMikito Inokuchi0Yoshitaka Fujimori1Sho Otsuki2Yuya Sato3Masatoshi Nakagawa4Kazuyuki Kojima5Department of Surgical Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, JapanDepartment of Surgical Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, JapanDepartment of Surgical Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, JapanDepartment of Surgical Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, JapanDepartment of Surgical Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, JapanDepartment of Minimally Invasive Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, JapanChemotherapy has become the global standard treatment for patients with metastatic or unresectable gastric cancer (GC), although outcomes remain unfavorable. Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed, and monoclonal antibodies targeting human epidermal growth factor receptor 2 (HER2) have become standard therapy for HER2-positive GC. An inhibitor of vascular endothelial growth factor receptor 2 or MET has also produced promising results in patients with GC. Fibroblast growth factor receptors (FGFR) play key roles in tumor growth via activated signaling pathways in GC. Genomic amplification of FGFR2 leads to the aberrant activation found in GC tumors and is related to survival in patients with GC. This review discusses the clinical relevance of FGFR in GC and examines FGFR as a potential therapeutic target in patients with GC. Preclinical studies in animal models suggest that multitargeted tyrosine kinase inhibitors (TKIs), including FGFR inhibitor, suppress tumor cell proliferation and delay tumor progression. Several TKIs are now being evaluated in clinical trials as treatment for metastatic or unresectable GC harboring FGFR2 amplification.http://dx.doi.org/10.1155/2015/796380 |
| spellingShingle | Mikito Inokuchi Yoshitaka Fujimori Sho Otsuki Yuya Sato Masatoshi Nakagawa Kazuyuki Kojima Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer Gastroenterology Research and Practice |
| title | Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer |
| title_full | Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer |
| title_fullStr | Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer |
| title_full_unstemmed | Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer |
| title_short | Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer |
| title_sort | therapeutic targeting of fibroblast growth factor receptors in gastric cancer |
| url | http://dx.doi.org/10.1155/2015/796380 |
| work_keys_str_mv | AT mikitoinokuchi therapeutictargetingoffibroblastgrowthfactorreceptorsingastriccancer AT yoshitakafujimori therapeutictargetingoffibroblastgrowthfactorreceptorsingastriccancer AT shootsuki therapeutictargetingoffibroblastgrowthfactorreceptorsingastriccancer AT yuyasato therapeutictargetingoffibroblastgrowthfactorreceptorsingastriccancer AT masatoshinakagawa therapeutictargetingoffibroblastgrowthfactorreceptorsingastriccancer AT kazuyukikojima therapeutictargetingoffibroblastgrowthfactorreceptorsingastriccancer |